ceritinib — CareFirst (Caremark)
Erdheim-Chester Disease (ECD)
Initial criteria
- Used for treatment of symptomatic or relapsed/refractory ALK-positive Erdheim-Chester Disease
- Used as a single agent
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months